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A single chain preparation of recombinant tissue-type plas- 
minogen activator W-PA) was compared with intravenous 
streptokinase to determine coronary thromholytic efficacy in 
patients with acute myocardial infarction <3 h old. Eighty- 
six patients were randomly selected to receive the intrave- 
nous cumulative dose of 100 mg rt-PA and 85 patients to 
receive 1.5 million units streptokinase. At 240 min after 
initiation of the thromholytic therapy noninvasive signs of 
sustained reperfusion occurred in 79% of patients in both 
groups (p = NS). Patency of the infarct-related vessel at 
follow-up angiography was observed in 81% of patients in 
the r&PA group and 74% of patients in the streptokinase 
group (p = NS). At hospital discharge, compared with 
admission, echocardiographically determined left ventricu- 
lar ejection fraction increased from 52 2 11% to 56 f 10% 
(p <: 0.01) in the rt-PA group; changes in the streptokinase 
group (50 + 9% to 51 f 11%) were not significant. 
Intravenous thrombolysis with recombinant human tissue- 
type plasminogen activator @t-PA) has been shown to com- 
pare favorably with intravenous streptokinase in acute myo- 
cardial infarction (1 ,I). Clot selectivity exhibited by rt-PA is 
expected to yield high reperfusion rates and avoid unneces- 
sary hemostatic breakdown (3). However, clot selectivity of 
rt-PA is relative rather than absolute and both the dose and 
the velocity of infusion determine the extent of systemic 
fibrinolytic activation (4). In addition, the drug does not 
distinguish between coronary thrombi and hemostatic plugs 
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A nadir value of <l g/liter fibrinogen plasma level 
occurred in 6 patients (7%) receiving rt-PA versus 74 
patients (87%) receiving streptokinase (p < 0.0001). 
Plasma levels of fibrin(ogen) degradation products were 
more than doubled in the streptokinase group (p < 0.01). 
One patient in the streptokinase group developed a fatal 
intracranial hemorrhage; five others showed a decline in 
hemoglobin 25 g/dl. Other clinical events in the streptoki- 
nase-treated group included allergic reactions (four pa- 
tients) and intrahospital reinfarction (two patients). None 
of these events occurred in the rt-PA group. This rt-PA 
preparation achieves a high rate of stable coronary reper- 
fusion, comparable with that of intravenous streptokinase 
and is associated with fewer complications and a significant 
sparing of the hemostatic system. 
(J Am Co11 Cardiol1989;13:19-26) 
that repair vascular lesions (5). Accordingly, bleeding com- 
plications are not entirely eliminated after rt-PA administra- 
tion (I). 
Recently, a new form of rt-PA has been developed to 
increase the shelf half-life and allow storage at room temper- 
ature. It consists mainly of single chain molecules and its 
efficacy in terms of coronary reperfusion and effects on the 
fibrinolytic system has recently been tested against both 
placebo and the old form of rt-PA consisting predominantly 
of two chain molecules (6-S). The focus of this study was to 
evaluate the coronary thrombolytic efficacy and the effects 
on left ventricular function of this new preparation in com- 
parison with the standard regimen of intravenous streptoki- 
nase (9). Secondary end points of this investigation included 
the evaluation of safety of the drug administration as well as 
the effects on components of the coagulation and fibrinolytic 
system. 
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Methods 
Patient selection. The study was conducted in eight coor- 
dinated centers. Patients were enrolled during a 12 month 
period between July 1986 and June 1987. To be eligible for 
treatment, patients had to satisfy the following inclusion 
criteria: 1) age between 20 and 70 years; 2) chest pain 
characteristic of myocardial ischemia for 230 min, unre- 
lieved by sublingual nitroglycerin; 3) ST segment elevation 
20.1 mV in two or more standard frontal plane leads or ~0.2 
mV in two or more precordial leads and ST segment depres- 
sion ~0.3 mV in two or more precordial leads; and 4) time 
elapsed from onset of ischemic pain to recruitment 
23 h. 
Eligible patients were excluded for the following reasons: 
I) previous myocardial infarction; 2) cardiogenic shock; 3) 
prolonged or traumatic heart massage or tracheal intubation; 
4) left bundle branch block; 5) uncontrolled hypertension 
(diastolic pressure ~110 mm Hg; systolic pressure 2200 mm 
Hg); 6) major liver or renal disease; 7) cerebrovascular 
accident within the last 3 months; 8) past or present bleeding 
disorder or significant gastrointestinal bleeding; 9) significant 
surgical procedure within the last 2 months; IO) previous 
coronary artery bypass surgery; 11) oral anticoagulant ther- 
apy; 12) childbearing age; 13) serious advanced illness; and 
14) anticipated problems with cardiac catheterization or 
inability to cooperate. 
Randomization. Eligible patients were noted in a log 
book and comprehensive data on all randomized patients 
were recorded in a basic case report form designed for 
computer analysis. At the time this study was planned, there 
was uncertainty about the reperfusion rates after thrombo- 
lytic therapy, because the Thrombolysis in Myocardial In- 
farction (TIMI) trial (1) had shown in the group assigned to 
streptokinase a reperfusion rate as low as 35%. Thus, we 
aimed for a total of 171 patients, 86 allocated to rt-PA and 85 
to streptokinase. Allocation was performed at random and 
balanced at each center. 
Protocol. After blood sampling for coagulation and other 
assays, patients randomized to the rt-PA group received the 
drug intravenously over 3 h at doses of 50, 20 and 20 mg at 
each successive hour with an initial bolus of 10 mg (total 
dose: 100 mg). The drug (Actilyse, supplied by Boehringer 
Ingelheim) was obtained by large scale suspension culture of 
mammalian cells transfected with cDNA encoding human 
t-PA and consisted predominantly of the one chain form of 
rt-PA. The patients allocated to streptokinase treatment 
received the drug intravenously over 60 min at the dose of 
1.5 million units (Streptase, Istituto Behring). At 180 min 
after the initiation of thrombolysis a heparin infusion was 
begun in both groups (bolus of 40 IU/kg followed by 1,000 
IUlh); the dose was adjusted to keep the level of the 
activated partial thromboplastin time at 1.5 to 2 times that of 
the control value. The anticoagulant treatment was main- 
tained until coronary angiography was performed. Because 
intravenous nitrates, concomitant with thrombolytic ther- 
apy, have been reported to increase the chances for achiev- 
ing reperfusion (IO,] l), probably through an increase of the 
coronary flow and a consequent greater delivery of throm- 
bolytic drug in the vicinity of the thrombus, all patients 
received intravenous nitroglycerin (at the maximal dose not 
associated with a ~10% decrease in systolic blood pressure 
or significant increase in heart rate) for the first 24 to 48 h. 
Noninvasive assessment of reperfusion. To minimize delay 
in treatment, coronary angiography was not performed be- 
fore thrombolysis and reperfusion was recognized by nonin- 
vasive criteria (12-15). To this end a 12 lead electrocardio- 
gram (ECG) was recorded and the patient was asked to grade 
the intensity of chest pain on an analogic visual scale from 0 
to 100, before starting thrombolysis. Subsequently, the I2 
lead ECG and intensity of chest pain were monitored at I5 
min intervals for up to 4 h and also whenever there was a 
change in symptoms, a change in ST segment shift on the 
monitor or a change in cardiac rhythm. 
In addition, blood samples for determination of serum 
creatine kinase (CK) and MB CK activity were drawn at 2 h 
intervals for the initial 16 h and every 4 h for the remainder 
of the first 24 h after thrombolysis; thereafter enzyme levels 
were determined 2 times daily during the second 24 h and 
then 1 time daily. All the ECGs, records of chest pain 
behavior and enzymatic time-activity curves were analyzed 
in a central laboratory by two investigators who did not 
know the treatment assignment. 
Reperfitsion NYU considered to have tclken place when the 
following three events occurred in a close temporal relation: 
1) an abrupt abatement or a progressive reduction of chest 
pain; 2) a reduction of magnitude of ST segment shift that 
continued in sequential ECGs until it was ~50% of the basal 
value; and 3) a rapid increase in serum levels of MB CK with 
the peak occurring within 13 h (16). 
The time inter& to reperfcrsion (reperfusion time) was 
defined as the interval from initiation of thrombolysis to the 
time of onset of the resolution of the ST segment elevation. 
The recurrence of ST segment elevation and chest pain 
during thrombolysis was taken as an indication of reocclu- 
sion (17). The noninvasive assessment of reperfusion was 
not feasible in nine patients (four in the rt-PA group and five 
in the streptokinase group) because of early death or incom- 
plete data. Enzymatic infarct size was measured according 
to the method of Sobel et al. (18). 
Coronary angiography. Contrast left ventricular and cor- 
onary angiograms were assessed in a central laboratory by 
two experienced cardiologists who were unaware of patient 
identity and treatment allocation. Angiograms were re- 
corded in multiple views including hemiaxial views for the 
left coronary artery. The infarct-related segment was iden- 
tified for all films on the basis of ECG and angiographic 
evidence. 
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Qurrlith~e r~ssessrnent of’ putency NYL~ perfor~nd M- 
cording lo (I pretletmnined code: 0 = normal vessel with 
complete filling of distal vessels within three cardiac cycles: 
I = <50% diameter stenosis with complete filling of distal 
vessels within three cardiac cycles; 2 = diameter stenosis 
between SO and 90%) with complete filling of the distal vessel. 
not through collateral vessels, within three cardiac cycles: 3 
= severe stenosis >90%, but complete filling of the distal 
vessel. not through collateral vessels. within three cardiac 
cycles: 4 = subtotal occlusion. no distal filling within three 
cardiac cycles; and 5 = total occlusion with or without 
collateral distal filling. Patency of the infarct-related vessel 
was identified by grade 0. I. 3 or 3, whereas occlusion was 
indicated by grades 4 and 5 (2.1920). 
Tllr hasc~linr sc\,rritq oj’c~oroncrp clrtery discrrsr HYIS tr1.w 
detrrrninrtl at the central laboratory by visual assessment of 
the percent reduction in luminal diameter of each coronary 
artery and its major branches. Left ventriculography was 
performed in the right anterior oblique projection; measure- 
ments of left ventricular e.jection fraction were obtained by 
the area-length method. Angiographic data were not ob- 
tained in eight patients in the rt-PA group and I I patients in 
the streptokinase group because of early death (n = I I), 
unwillingness to undergo the procedure (n = 6) or techni- 
cally inadequate films (n = 2). 
Echocardiography. Two-dimensional echocardiograph] 
was performed on the day of admission. after the adminis- 
tration of thrombolytic therapy and before hospital dis- 
charge. Each study consisted of parasternal long- and short- 
axis views and apical two and four chamber views. In 
patients in whom these views were suboptimal, the subxi- 
phoid window was utilized. For the purpose of analysis the 
left ventricle was divided into I I segments considering the 
apex as a single segment. Each myocardial segment was 
scored for wall motion using semiquantitative visual analysis 
score: normal motion 0. hypokinesia I, akinesia 2. dyskine- 
sia 3 and aneurb’sm 4. Therefore, a left ventricular index 
score was constructed for each study. Left ventricular 
ejection fraction was calculated according to Simpson’s rule. 
Each study was recorded on videotape and later scored 
independently in a central hbOrdtOry by two observers who 
were unaware of patient identity. therapy and effects of 
therapy. One hundred sixteen patients had a satisfactory 
examination both on admission and before discharge; 61 
patients were treated with rt-PA and 55 with streptokinase. 
Blood coagulation tests and evaluation of bleeding compli- 
cations. Venipunctures were performed atraumatically with 
I9 gauge needles using a two syringe technique. Blood 
samples (9 vol) were collected on citrate (I vol) (final 
concentration 0.01 M) or on citrate containing aprotinin 
(Trasylol, Bayer) (final concentration 200 kIU/ml) before and 
90 and I80 min after the beginning of thrombolysis. Blood 
was centrifuged within I h and plasma frozen immediately. 
Fibrintogen) level5 were measured by a clotting rate assal 
Table I. Patient Data Before Thrombolvsis 
rt-P.4 Group SK Group 
Bareline Characteristics (n = X6) In = 85) p Value 
Age (yrl 5-J * x 5x 2 8 NS 
blen:Women 71,li 66:19 NS 
Body \icight (kg) 7T ? II 73 - 12 NS 
Height (cm) 170 - : I67 i 7 NS 
Chnical hAor) (/iI I ‘7 ) 
Zngina pectorig Y (321 _ i‘l (JO) NS 
Hppertenwn 19 13.l) 33 140) NS 
Diabetes x (9) 13 115) NS 
Hyperlipidemia IX (71) 14 (1X) NS 
Smoker\ 62 ii3 i! (62) NS 
Delay time from onset of symptom\ 17-l T 30 117 + 31 NS 
lo treaiment (min) 
Sy\tohc BP (mm Hg) I.13 i 22 I35+?I NS 
Diastolic BP (mm Hg) 8Ji I? XJ i- II NS 
Heal-t rahe (min ‘1 7X + I5 7; z I6 NS 
Site of necro& (.4ntllnf) ‘wll 37’48 NS 
Ant = anterior; BP = blood pressure: Inf = mfermr, rr-PA = recombinant 
tiuue-rbpe pla\minugen activator: SK = weptokinase. 
(2 I): other assays included fibrin and fibrinogen degradation 
products (22). plasminogen (with use of chromogenic sub- 
strate S-22.51, Kabi Diagnostica) (23) and cu,-antiplasmin 
(24). These measurements were made in two experienced 
coagulation laboratories. Activated partial thromboplastin 
time as well as the prothrombin time were measured con- 
ventionally by the hospital central hematology laboratory. 
The values of plasminogen, c+ antiplasmin and prothrombin 
time were expressed in percent by comparison with a 
standard curve obtained by serial dilutions of a normal 
plasma pool. Bleeding was characterized by site and quali- 
fied as “major” if there was a decrease in hemoglobin ~5 gi 
dl or any intracranial bleeding (8). 
Statistical analysis. All values are expressed as mean 2 I 
SD. Paired and unpaired t tests were used to compare the 
means of continuous variables. Data that did not follow the 
normal distribution were compared by an appropriate non- 
parametric test (Mann-Whitney U test). Chi-square tests 
(with Yates’ correction when indicated) were used to com- 
pare discontinuous variables. A two-tailed method was used 
throughout and a 0.05 level of significance was used as a 
criterion to reject the null hypothesis. 
Results 
Patient data (Table 1). The two groups (rt-PA versus 
streptokinase) were similar in age, gender ratio. cardiovas- 
cular characteristics, site of infarction and interval between 
the onset of pain and the initiation of thrombolysis. The full 
treatment dose was administered to all 86 patients allocated 
to the rt-PA group. The infusion of streptokinase was 
stopped in 4 (4.7%) of the 85 patients because of severe 
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Table 2. Noninvasive Assessment of Reperfusion in the First 240 Table 3. Cardiac Catheterization Data After Thrombolysis 
min After Thrombolysis (Central Laboratory) (Central Laboratory) 
rt-PA Group 
(n = 82) 
SK Group 
(n = 80) p Value 
Hours after infusion 
(mean 2 SD) 
Infarct vessel patency* 
Grade 0 
rt-PA Group SK Group 
(n = 78) (n = 74) p Value 
98 + 41 95 + 47 NS 
3 3 
Patients showing reperfusion 
Reperfusion time (mm) 
Patients showing reocclusion 
Time of reocclusion (after 
71 (87%) 64 (80%) NS 
78 ? 48 81 236 NS 
20 (24%) 8 (10%) co.02 
77 i: 57 48 C 41 NS 
reperfusion) (min) Grade 1 4 3 
Patients showing reperfusion 14 (70%) 7 (87%) NS Grade 2 I5 I8 
(after reocclusion) Grade 3 41 30 
Duration of reocclusion (min) 37 t 33 26% I3 NS Grade 4 I 1 
Patients with sustained 
reperfusion at progressive 
time intervals 
30 min 
60 min 
90 min 
120 min 
180 min 
240 min 
I3 (16%) 
30 (37%) 
47 (57%) 
61 (74%) 
61 (74%) 
65 (79%) 
1 (I%) 
27 (34%) 
45 (56%) 
53 (66%) 
63 (79%) 
63 (79%) 
co.05 
NS 
NS 
NS 
NS 
NS 
Grade 5 
Overall patency 
(grade 0, 1, 2, 3) 
Number of vessels with ~50% 
stenosis 
None 
One 
Two 
Three 
14 19 
63 (81%) 55 (74%) NS 
2 (3%) 2 (3%) 
28 (36%) 26 (35%) NS 
33 (42%) 24 (32%) 
I5 (19%) 22 (30%) 
Abbreviations as in Table I. Left ventricular end-diastolic 
pressure (mm Hg) 
Preangiography I8 ? 7 I9 ? 8 NS 
hypotension (2 patients) or allergic reaction (2 patients). The 
decrease in blood pressure was transient. 
Postangiography 
Left ventricular ejection 
fraction (R) 
22 ? 8 22 k 8 NS 
55? 11 53 + IO NS 
Reperfusion rates (Table 2). The overall estimated reper- 
fusion rate was high in both groups (87% in the rt-PA versus 
80% in the streptokinase group, p = NS). On average the 
reperfusion time was 78 min in the rt-PA group and 81 min in 
the streptokinase group (p = NS). The recurrence of chest 
pain and ST segment elevation, however, was frequent after 
reperfusion; these signs of estimated reocclusion occurred in 
20 patients in the rt-PA group (24%) and 8 patients in the 
streptokinase group (lo%, p = 0.015) with a delay, respec- 
tively, of 77 versus 48 min (p = NS). The reocclusion was 
transient in 14 patients in the rt-PA group (70%, mean 
duration of reocclusion 37 min) and in 7 patients in the 
streptokinase group (87%, mean duration of reocclusion 26 
min) (p = NS). As a result, the ultimate reperfusion rate at 
240 min after initiation of thrombolysis was 79% in both 
groups. Plasma MB CK activity peaked at 10.8 2 4.9 h in the 
rt-PA group and at 10.5 t 4.4 h in the streptokinase group (p 
= NS). Enzymatic infarct size was, respectively, 37.6 ? 24.6 
*See text for definition. Abbreviations as in Table I. 
ejection fraction did not differ significantly between the two 
groups at the time of hospital admission. In the rt-PA group 
left ventricular ejection fraction improved from 52 + 11% to 
56 + 10% before hospital discharge (p < 0.01). Similarly the 
left ventricular index score decreased from 0.42 ? 0.39 to 
0.33 t 0.31 (p < 0.01). No significant improvement in 
ejection fraction was observed in the streptokinase group, 
whereas the left ventricular index score decreased from 0.47 
* 0.37 to 0.40 t 0.37 (p < 0.05). 
Clinical outcomes (Table 5). During the first 180 min from 
the beginning of thrombolysis, the prevalence of hypoten- 
sion was almost doubled in the streptokinase group (22 
versus 12%) but the difference was not statistically signifi- 
and 32.0 2 20.6 g-Eq/m2 (p = NS). Table 4. Echocardiogranhic Data (Central Laboratorv) 
Angiographic data (Table 3). Cardiac catheterization was 
performed later in the hospital course 98 ? 41 h after rt-PA 
infusion and 95 2 47 h after streptokinase infusion (p = NS). 
There was a 7% difference between the groups in patency of 
the infarct-related vessel (81% in the rt-PA-treated group 
and 74% in the streptokinase-treated group, p = NS). More 
LVlS 
Admission* 
Discharge 
I VFF /a1 
_ . 
r&PA Group 
(n = 61) 
0.42 ? 0.39 + 
0.33 ? 0.31 
_ 
SK Group 
(n = 55) p Value 
0.47 ? 0.37 NS 
0.40 ? 0.37 t: NS 
than 60% of patients had multivessel disease. Left ventricu- Y~~m~~~~oion* 52 k 11 
lar end-diastolic pressure and ejection fraction were similar Discharge 56 ? 10 
$: 50*9 8 NS 
51 + 11 0.05 
in the two groups. 
Echocardiographic data (Table 4). Echocardiographically 
determined left ventricular regional wall motion score and 
*Within 24 h after thrombolysis; tp < 0.01; jp < 0.05; $no significance. 
LVEF = left ventricular ejection fraction; LVIS = left ventricular index 
score. Other abbreviations as in Table I. 
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Table 5. Events During Hospitalization 
During I5t 180 min From 181 min to Dixharge 
rt-P.4 Group SK Group rr-PA Group SK Group 
(n = X6) (n = x51 (ll = X6) (I1 XSI 
Ikcrease of \y\tolic BP to 
~90 mm Hg 
(‘ardiogenic \hock 
I’idmonary edema 
Bradycardia (150 beatslmin) 
.\V block (2nd or 3rd’) 
.\tl-ial fibrillation 
.\ccelerated idioventricular rhythm 
/x I00 beathmin) 
Ventricular tachycardia 
I P 100 beats’min) 
Ventricular fibrillation 
i’el-icarditi5 
Kecurrence of ixhemia 
I)etinite reinfarction 
\Ilrrgic reactlons 
Morlalit! 
IO 
0 
0 
13 
II 
4 
70 
0 
0 
4 2 9 
4 I 
8 15 I3 
0 2 
-I I) 0 
0 1 1 
p < 0.01: .AV = atrioventricular: BP = blood prewre. Other abbreviations as m Table I 
cant (p = 0.09). In addition four patients in the streptokinase 
group developed allergic reactions. Patients treated with 
rt-PA showed a more frequent occurrence of accelerated 
idioventricular rhythm (14% versus 6%: p = 0.07) and 
recurrence of chest pain, as outlined in the reperfusion 
section. During the subsequent hospital course clinical and 
ECG findings of recurrent myocardial ischemia occurred in 
IS patients (17%) assigned to rt-PA treatment and 13 patients 
(IS’%) assigned to streptokinase treatment. However. only 
two patients in the streptokinase group versus none in the 
rt-PA group developed a definite reinfarction (confirmed by 
recurrent MB CK elevation). lntrahospital mortality was 
lower in the rt-PA group (four versus seven patients: 4.6% 
versus 8.2% [p =: NS]). In the rt-PA group, the cause of 
death was cardiogenic shock in three patients and electro- 
mechanical dissociation in one patient. In the streptokinase 
group, death was due to cardiogenic shock in two patients 
and to pulmonary edema in two: one patient each died of 
electromechanical dissociation, reinfarction or intracranial 
bleeding. 
Hemostatic variables and bleeding complications (Tables 6 
and 7). During the infusion of rt-PA, fibrinogen levels de- 
creased to 81% of the preinfusion levels at 90 min and to 63% 
after I80 min. In the streptokinase group fibrinogen levels 
decreased, respectively, to 21% and 16% (both p < 0.01). A 
decrease below 1 g/liter was observed in two patients in the 
rt-PA group at 90 min and in six patients at 180 min and. 
respectively. in 61 and 74 patients in the streptokinase group 
(both p < 0.0001). The fibrin(ogen) degradation products 
levels were much higher in the streptokinase group at 90 and 
at 180 min (both p < 0.01). The decrease in plasma plasmi- 
nogen activity was less in rt-PA patients at 90 and at I80 min 
(both p < 0.01). However. alpha,-antiplasmin was almost 
exhausted in both groups, with no significant difference 
between the 78% reduction at 180 min in the rt-PA group 
compared with the 86% reduction in the streptokinase group. 
Table 6. Hemostatic Variables During Thrombolytic Therapy (Central Laboratory) 
Fibrinogen img/dl) 
Plasminogen (%I 
FDP (pgml) 
Alpha:-antiplasmin (??I 
aPTT ($1 
Prothrombin time (r/;) 
Pretreatment 90 Min 
rt-PA SK p Value rl-PA SK p Value 
306 t x4 29x 2 83 NS 7.39 2 61 hl i 59 <O.Ol 
99 ? ?I I00 -t 24 NS 53 f 14 I7 i I5 CO.01 
727 IO 2 I9 NS I30 * I07 303 z I60 ‘Co.01 
91 i 24 93 i- 33 NS 21 f 26 I6 i 23 CO.01 
25 i- 6 25 i 5 NS 35 + 20 63 z 32 CO.01 
91 i I3 91 + II NS 74 f 22 31 f !I <O.Ol 
I80 Min 
rt-PA SK p Value 
IX6 ? 5X 41 -t 31 CO.01 
46 t 21 I5 f I3 <O.Ol 
172 i 144 302 2 118 CO.01 
20 f 23 I4 2 !I NS 
41 t 22 hh + 30 10.01 
h4 i 10 18 r I7 10.01 
FDP = fibrin(ogenl degradation products: aPTT = activated partial thromboplasrm time. Other abbreviations as in Table I 
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Table 7. Bleeding Complication 
&PA Group SK Group 
(n = 86) (n = 85) p Value 
Total patients 
Site of bleeding 
intracranial 
Gastrointestinal 
Other 
Decrease in hemoglobin (gidl) 
25 
>3 <5 
>3 
8 (9%) 6 (7%) NS 
0 I NS 
2 I NS 
6 4 NS 
0 5 (6%) 0.02 
I2 (14%) 17 (20%) NS 
I2 (14%) 22 (26%) 0.05 
rt-PA = recombinant tissue-type plasminogen activator: SK = streptoki- 
nase. 
Global clotting assays were altered more consistently in the 
streptokinase group. 
During the first 180 min, when only thrombolytic agents 
were infused, one patient in each group developed bleeding 
at puncture sites. One additional rt-PA patient showed 
oozing from the gums. When heparin was added, bleeding 
complications cumulated to a total of 9% in the rt-PA group 
and 7% in the streptokinase group (p = NS). Bleeding 
complications were easily managed, with the exception of a 
fatal intracranial hemorrhage in one patient in the streptoki- 
nase group. The proportion of patients showing a decline in 
hemoglobin >3 g/dl was significantly higher in the strepto- 
kinase group (26% versus 14%; p = 0.05). No patient in the 
rt-PA group showed a decline 25 gidl, as opposed to five 
patients assigned to streptokinase treatment (p = 0.02). 
Discussion 
Coronary reperfusion with single chain rt-PA versus strep- 
tokinase. In this study a comparison was made between 
single chain rt-PA (2.5) at the recently recommended total 
intravenous dose of 100 mg (26) and intravenous streptoki- 
nase (1.5 million units over 60 min). Previous comparisons 
between rt-PA and streptokinase were performed using 
double chain rt-PA (1,2). The study was single blind and 
patients were randomized 43 h of the onset of symptoms. 
Reperfusion was detected noninvasively by frequent assess- 
ment of ST segment elevation, chest pain intensity and 
enzyme washout. This method has a sound physiologic basis 
and has been extensively validated from a clinical point of 
view (12-U). Data provide additional information about the 
thrombolytic process that is not immediately available when 
analyzing coronary patency at a single predetermined time 
after infusion of the thrombolytic agent. Reperfusion time 
varied widely among individuals and signs of reocclusion 
after reperfusion were frequently observed. The rate of 
reperfusion was significantly higher in the rt-PA group than 
in the streptokinase group during the first 30 min, but 
subsequent reocclusions were more frequent with rt-PA. As 
a result, the proportion of patients showing sustained reper- 
fusion was similar in both groups (79% at 240 min after the 
beginning of thrombolysis). These high reperfusion rates 
might be explained by the short duration of symptoms before 
treatment, and support the in vitro observations of an 
increased resistance of thrombi to lysis as they age, because 
of continuing polymerization and cross-linking of the fibrin 
(27). 
Coronary patency. Coronary angiography was performed 
on average 4 days after hospital admission in both groups. 
The infarct-related vessel was found patent in 81% of pa- 
tients in the rt-PA group and in 74% of patients assigned to 
streptokinase treatment. These data, consistent with a pre- 
vious observation (20), suggest that the recurrence of ische- 
mic episodes during and immediately after thrombolysis with 
rt-PA may be transient and that the risk of late stable 
coronary reocclusion with this agent is not higher than the 
risk with streptokinase. These results are also in agreement 
with the observation that no patients in the rt-PA group and 
only two in the streptokinase group developed clinical signs 
of reinfarction during the hospital stay. 
Hemostasis. The results of this study confirm that the 
fibrinolytic system is activated during the infusion of single 
chain rt-PA (28). However, the hemostatic defect was less 
marked than that observed in the streptokinase group. The 
52% decline in plasma plasminogen activity in the rt-PA 
group was significantly lower than that in the streptokinase 
group (82%). Although the activity of the naturally occurring 
inhibitor alpha,-antiplasmin was almost exhausted in both 
groups, plasma levels of fibrin(ogen) degradation products 
were much higher in the streptokinase group. Fibrinogen 
levels decreased to <I g/liter in only 6 (7%) patients in the 
rt-PA group as opposed to 74 patients (87%) treated with 
streptokinase. 
Bleeding complications. Bleeding complications are still 
to be expected in patients treated with rt-PA, particularly 
when cardiac catheterization is performed before and during 
thrombolysis (1.7,s). In this study early cardiac catheteriza- 
tion was avoided and, accordingly, bleeding rates were 
lower than those in previous studies. Although significant 
bleeding events were rare with both thrombolytic agents. 
one patient in the streptokinase group developed a fatal 
intracranial hemorrhage; on the whole, decreases in hemo- 
globin were significantly more frequent and larger after 
streptokinase infusion. Because all hemorrhagic complica- 
tions took place after full heparinization had been under- 
taken, it is difficult to attribute their frequency to thrombo- 
lytic agents alone. Heparin, in addition to its anticoagulant 
action, causes several lipolytic enzymes to be released into 
the circulation and leads to raised levels of plasma free fatty 
acid concentration (29), which may exert deleterious effects 
during reperfusion (30). Hence, the role of intravenous 
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heparin in the setting of thrombolytic therapy must be 
elucidated. 
Conclusions. Single chain rt-PA, at the recently recom- 
mended intravenous cumulative dose of 100 mg, yields high 
coronary reperfusion rates (79%). The patency of the infarct- 
vessel at follow-up angiography (81%) along with the ab- 
sence of reinfarction during the hospital stay confirm that the 
risk of sustained reocclusion is low. In comparison with 
intravenous streptokinase the hemostatic system was signif- 
icantly spared. The infusion of rt-PA was not associated with 
intracranial bleeding and allergic reactions. Further advan- 
tages over streptokinase, in terms of mortality and morbid- 
ity, are to be tested by larger scale clinical trials. 
We are indebted to Ptofeswr E. Ambrorioni (Cattedra do Terapia Medtca 
dell’Umverrtth e Servirio di Farmaculogia Clinica del Policlinico S. Orsola. 
Bologna. Italy) for asststance in the preparation of the study protocol. 
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Boehringer Ingelheim. Florence, Department of Clinical Research. luigl 
Visani. MD 
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